MoonLake Immunotherapeutics
MLTX10.630USD
+0.340+3.30%
종가 11/07, 16:00（ET）시세는 15분 지연됩니다
677.18M시가총액
손실P/E TTM
자세한 내용은 MoonLake Immunotherapeutics 회사
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics 정보
종목 코드 MLTX
회사 이름MoonLake Immunotherapeutics
상장일Oct 20, 2020
CEODr. Jorge Santos Da Silva
직원 수100
유형Ordinary Share
회계 연도 종료Oct 20
주소Dorfstrasse 29
도시ZUG
증권 거래소NASDAQ Capital Market Consolidated
국가Switzerland
우편 번호6300
전화41415108022
웹사이트https://moonlaketx.com/
종목 코드 MLTX
상장일Oct 20, 2020
CEODr. Jorge Santos Da Silva
MoonLake Immunotherapeutics의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Tue, Nov 4
마지막 업데이트: Tue, Nov 4
주주
주주 유형
주주
주주
비율
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
기타
50.37%
주주
주주
비율
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
기타
50.37%
주주 유형
주주
비율
Hedge Fund
41.51%
Investment Advisor
20.11%
Investment Advisor/Hedge Fund
17.19%
Individual Investor
11.03%
Research Firm
2.11%
Venture Capital
1.30%
Bank and Trust
0.07%
Pension Fund
0.05%
기타
6.62%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.31M
8.36%
-114.00K
-2.10%
Jun 30, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
T. Rowe Price Associates, Inc.
2.61M
4.12%
-360.60K
-12.13%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Citadel Advisors LLC
1.67M
2.64%
+195.41K
+13.22%
Jun 30, 2025
Westfield Capital Management Company, L.P.
1.26M
1.98%
-175.39K
-12.22%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.26M
1.98%
-19.32K
-1.52%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Thu, Nov 6
마지막 업데이트: Thu, Nov 6
이름
비율
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.16%
Goldman Sachs Future Health Care Equity ETF
0.12%
Virtus LifeSci Biotech Clinical Trials ETF
0.12%
JPMorgan Healthcare Leaders ETF
0.03%
First Trust IPOX Europe Equity Opportunities ETF
0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Blue Chip Growth ETF
0.01%
더 보기
ALPS Medical Breakthroughs ETF
비율0.27%
Global X Guru Index ETF
비율0.16%
Goldman Sachs Future Health Care Equity ETF
비율0.12%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.12%
JPMorgan Healthcare Leaders ETF
비율0.03%
First Trust IPOX Europe Equity Opportunities ETF
비율0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
비율0.01%
John Hancock Multifactor Small Cap ETF
비율0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
비율0.01%
Fidelity Blue Chip Growth ETF
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
